271 results about "Tumor immunity" patented technology

The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.

The present invention describes a method for identification and labeling of sentinel lymph nodes (SLNs) and the presence or absence of lymph node metastases as an important diagnostic and prognostic factor in early stage cancers of all types. The method, know as Molecular Lymphatic Mapping, uses traditional dye/radioactive tracer based techniques in conjunction with a nucleic acid marker to identify and label the SLN, not only for current diagnostic methods, but for archival purposes. In addition, MLM can be used to deliver a therapeutic gene or genes to the SLN to activate tumor immunity to tumor cells, and/or to inhibit tumor metastases. The methods may be combined with therapeutic intervention including chemotherapy and radiotherapy.

Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.

A method of generating an anti-tumor immune response using a cationic molecule:biologically active molecule complex is provided. In one embodiment, the anti-tumor immune response is a protective, memory-based response. The complex may be administered alone, as the active ingredient in a formulation, or as an adjuvant. The invention also provides for methods of generating an immunostimulatory response against the tumor cell present during treatment by exposing a cationic molecule:biologically active molecule complex to a mammalian cell or a foreign tumor cell.

The invention discloses a KIR and ligand genetic typing experimental method. By the technology, the time and labor are saved, and meanwhile, DNA sample capacity is further saved. A multi-PCR technology is adopted, meanwhile, 36 pairs of primers are further combined according to the sizes of PCR products, and finally, amplified reaction is finished in 12 reaction holes. The KIR and ligand genetic typing experimental method is conveniently applied to amplification of 96 pore plates, conventional Taq enzyme is used, typing of all KIR genes and ligands thereof can be finished at a time under the same reaction conditions, and the practicality of the KIR and ligand genetic typing experimental method is greatly improved. Two pairs of primers are used for a KIR gene, the accuracy is improved, anda false negative result is avoided. The KIR gene can be combined to MHC-I type ligand molecules on the surfaces of targeting cells, inhibiting or activating signals are transmitted to regulate the activity of NK cells and T cells, and the KIR and ligand genetic typing experimental method plays an important regulation role in hematopoietic stem cell transplantation, feto-matemal tolerance, anti-infectious immunity, tumor immunity and autoimmune diseases. Therefore, KIR genetic typing facilitates understanding of influences of KIR to tumor immunity, hematopoietic stem cell transplantation and autoimmune diseases.

Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

The invention provides isolated recombinant oncolytic poxvirus, a pharmaceutical composition and use thereof in the treatment of tumors and/or cancer. The isolated recombinant oncolytic poxvirus is TKgene and the VGF gene functionally deficient type, an exogenous IL-21 gene is integrated in the genome of the recombinant oncolytic poxvirus, and the IL-21 gene can be expressed in tumor cells. The recombinant oncolytic poxvirus can be selectively replicated in tumor cells, and can fully exert the anti-tumor immunity of the exogenous IL-21, so that the oncolytic killing effect of the oncolytic virus and the anti-tumor immune stimulation effect of IL-21 can produce a synergistic effect.

It is intended to provide highly safe antitumor agents which exhibit an antitumor effect on human remote tumors such as metastatic tumors too and by which an antitumor immune reaction enabling an immune therapy for cancer can be induced, tumor immunity inducers, T cell activators, dendritic cell activators, a method of treating cancer using the same, etc. Inactivated herpes simplex virus (inactivated HSV), herpes simplex virus glycoprotein D (HSVgD), etc. are employed as the active ingredients of antitumor agents, tumor immunity inducers, T cell activators or dendritic cell activators. As a specific example of the treatment for the above-described inactivation, citation may be made of a combination of UV-irradiation using ultraviolet light at 254 nm at 4 J/m² for 30 minutes with heating at 56° C. for 30 minutes.

The invention discloses SUMOylation modification which can be carried out at the K288th site of deacetylase SIRT3 dependent on NAD in a mitochondrion as well as modulation and control of activity of SIRT3; meanwhile, SUMO specific protease 1 (SENP1) can modulate and control SUMOylation modification of the SIRT3, so that related physiological and pathological processes in which SIRT3 participatingof mitochondrion are modulated and controlled; the modulation and control effect of the SENP1 depends on phosphorylated modification of an SENP1S180 site. The invention discloses the influence of a signal modulation and control path of an SENP1-SIRT3 shaft on metabolism of the mitochondrion, the activation of macrophage and T cells, and tumor immunity and tumor growth; therefore, a significance onprevention and treatment of diseases related with mitochondria metabolism and tumor is realized.

The invention provides a tumor immunity type nutritional composition. The tumor immunity type nutritional composition comprises a high-energy total-nutrient composition and an immune regulation component, wherein the high-energy total-nutrient composition comprises a protein source, a saturated fatty acid source and a carbohydrate source; the immune regulation component comprises new good materials, fungi and unsaturated fatty acid; the new food materials are selected from ginseng or tea polyphenol; the fungi are selected from lentinula edodes, tremella and coprinus comatus; the unsaturated fatty acid is selected from fish oil, purple perilla seed oil and seabuckthorn seed oil; and the mass ratio of the high-energy total-nutrient composition to the immune regulation component is (80-92): (8-20). The product disclosed by the invention is an immune formula which is high in protein, high in fat, low in sugar and high in energy; the energy substances provided by the protein, the fat and the carbohydrate are 18-25%, 48-55% and 25-32%, respectively; and by adopting a high-fat emulsification and micro-capsule embedding technology, the produced tumor immunity type nutritional composition is high in stability and slow in release, and is capable of relieving the symptoms such as negative nitrogen balance and lean body mass loss of the tumor patients, particularly the lung cancer and breast cancer patients.

The invention belongs to the technical field of molecular biology and in particular relates to a preparation method of a PD-1 (Programmed cell death protein 1) and CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) double-gene defect type T lymphocyte preparation. Construction of a PD-1 and CTLA4 double-gene knockout vector, T lymphocyte separation and activation, electric transfection of T lymphocytes and T7E1 enzyme digestion identification, and flow cytometer screening and sequencing analysis are carried out. According to the production of a gene defect type immune cell preparation, on one hand, a production procedure of cells is simplified; on the other hand, the capability of killing tumor cells by the T lymphocytes is improved and the long-period tumor immunity can be enhanced.

The invention discloses a natural killer cell modified by specific chimeric antigen receptor gene and a preparation method and use thereof. The natural killer cell modified by specific chimeric antigen receptor gene comprises a NY-ESCO-1 specific chimeric antigen receptor gene and a truncated spleen tyrosine kinase Syk gene. The preparation method simultaneously infects the natural killer cell with a slow virus containing the NY-ESCO-1 specific chimeric antigen receptor gene and a slow virus containing the truncated spleen tyrosine kinase Syk gene. By the combined action of the NY-ESCO-1 specific chimeric antigen receptor gene and the truncated spleen tyrosine kinase Syk gene, the natural killer cell modified by the specific chimeric antigen receptor gene improves the targeted tumor cell specific lethality of the natural killer cell, improves the ability of activating downstream signals of the natural killer cell, avoids the escape of tumor immunity, and accordingly enhances the killing activity on the tumor cell.

The invention relates to a tumor antigen loaded polydopamine nanoparticle, and a preparation method and an application thereof. The tumor antigen loaded polydopamine nanoparticle is prepared by covalently connecting a tumor antigen to the surface of a polydopamine nanoparticle through Michael addition and Schiff base reaction, wherein the tumor antigen comprises, but is not limited to, one or moreselected from the group consisting of a specific tumor antigen peptide fragment, a tumor cell lysate, a specific tumor antigen DNA fragment and an adjuvant CpG. The tumor antigen loaded polydopaminenanoparticle prepared by using the method provided by the invention has good biocompatibility, can effectively activate in-vivo anti-tumor immunity, significantly inhibits the growth of tumor cells, can improve the tumor immunosuppressive microenvironment, further enhances the anti-tumor activity of the human body, can be used for immune treatment of tumors, and is simple and pollution-free in preparation method.

The invention discloses an anti-tumor immunity-enhancing traditional Chinese medicine preparation which comprises the following components by weight parts: 10-30 parts of ginseng, 2-7 parts of thunder god vine, 10-30 parts of lanceolata, 10-30 parts of astragalus, 10-30 parts of angelica, 10-30 parts of glaucescent fissistigma root, 10-30 parts of grey polypore, 10-30 parts of fleece-flower roots, 10-30 parts of spatholobus stems, 10-30 parts of dandelion, 10-20 parts of toad skin, 10-20 parts of gecko, 10-30 parts of safflower, 10-30 parts of medlar, 10-30 parts of cinnamon, 10-20 parts of hydnoid mushrooms, 10-30 parts of atractylodes and 10-30 parts of gamboges. The traditional Chinese medicine preparation by the scientific compatibility of medicines can tonify the kidney, einforce deficiency, activate and nourish blood, improve the autoimmunity of human bodies, promote blood circulation by removing blood stasis and dissolving lumps and effectively inhibit tumor growth.